Skip to Main Content
Contribute Try STAT+ Today

The California Board of Pharmacy is seeking to revoke or suspend a pharmacy license held by OptumRx, which is one of the largest pharmacy benefit managers in the U.S., for a series of prescribing failures that allegedly jeopardized patient health.

The infractions, which occurred between 2016 and 2020, involved failures to refill prescriptions promptly; substituting a medicine without written consent; telling a patient his health insurer denied a refill due to cost; and dispensing a generic version of a drug with a costly co-pay when the customer had no co-pay for the brand version, according to the complaint, which was filed in August but shared online recently by the agency.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment